杉本 真也 (スギモト シンヤ)

Sugimoto, Shinya

写真a

所属(所属キャンパス)

医学部 内科学教室(消化器) (信濃町)

職名

助教(有期)

学歴 【 表示 / 非表示

  • 2003年04月
    -
    2009年03月

    慶應義塾大学, 医学部

    大学, 卒業

  • 2014年04月
    -
    2018年03月

    慶應義塾大学, 医学研究科医学研究系専攻

    大学院, 修了, 博士

学位 【 表示 / 非表示

  • 博士(医学), 慶應義塾大学, 課程, 2018年03月

    Reconstruction of the Human Colon Epithelium In Vivo

 

研究分野 【 表示 / 非表示

  • ライフサイエンス / 消化器内科学

研究キーワード 【 表示 / 非表示

  • オルガノイド

  • 潰瘍性大腸炎関連腫瘍

  • 炎症性腸疾患

  • 短腸症候群

  • 腸管上皮幹細胞

 

著書 【 表示 / 非表示

  • Organoid derivation and orthotopic xenotransplantation for studying human intestinal stem cell dynamics

    Sugimoto S., Fujii M., Sato T., Methods in Molecular Biology, 2020年

     概要を見る

    Intestinal stem cells continuously self-renew throughout life to maintain gut homeostasis. With the advent of the organoid culture system, we are now able to indefinitely expand healthy and diseased tissue-derived human intestinal stem cells in vitro and use them for various applications. Nonetheless, investigating the behavior of human intestinal stem cells in vivo still remains challenging. We recently developed an orthotopic xenotransplantation system that realizes in vivo reconstruction of human intestinal epithelial tissue with preserved stem cell hierarchy by engrafting human normal colon organoids onto the mouse colon surface. We also introduced new growth factors, namely, insulin-like growth factor-1 (IGF-1) and fibroblast growth factor-2 (FGF-2), into the culture condition for human intestinal organoids that significantly increase scalability and transfectability of the organoids. By integrating these recent advances, we organized a tissue-oriented platform encompassing derivation of patient-derived intestinal organoids and their orthotopic xenotransplantation. The research platform based on orthotopic xenotransplantation of human intestinal organoids provides a powerful tool for studying human intestinal stem cell biology in native tissue-relevant contexts as well as for establishing novel disease modeling systems.

  • Establishment of 3D intestinal organoid cultures from intestinal stem cells

    Sugimoto S., Sato T., Methods in Molecular Biology, 2017年

     概要を見る

    The intestinal epithelium is the most rapidly renewed tissue in adult mammals, and its renewal is strictly controlled by intestinal stem cells. Extensive studies using genetic models of intestinal epithelium have revealed the mechanisms underlying the self-renewal of intestinal stem cells. Exploiting this knowledge, we developed a novel 3D culture system that enables the outgrowth of intestinal Lgr5+ stem cells derived from mouse and human tissues into ever-expanding crypt–villus mini-guts, known as intestinal epithelial organoids. These organoids are maintained by the self-renewal of stem cells and give rise to all differentiated cell types of the intestinal epithelium. Once established, organoids can be cryopreserved and thawed when needed. This culture system has been widely used for studying stem cell behavior and gene function and for disease modeling.

論文 【 表示 / 非表示

  • Water Does Not Mix with Lipids: Water-assisted Colonoscopy.

    Sugimoto S, Takabayashi K, Kanai T

    Internal medicine (Tokyo, Japan) 2022年07月

    ISSN  0918-2918

  • Efficacy of Calcineurin Inhibitors for Induction of Remission in Intestinal Behçet's Disease

    Kawaguchi T., Fukata M., Omori T., Kiyohara H., Sugimoto S., Nanki K., Sujino T., Mikami Y., Kanai T.

    Crohn's and Colitis 360 (Crohn's and Colitis 360)  4 ( 3 )  2022年07月

     概要を見る

    Background: The efficacy of calcineurin inhibitors (CNIs) for induction of remission in intestinal Behçet's disease (intestinal BD) has not been explored. Methods: A multicenter retrospective case series study of patients with active intestinal BD treated with CNIs (cyclosporin and tacrolimus) was conducted. Results: Of 16 patients, 12 (75%) showed a clinical response and 5 (31.3%) achieved clinical remission after 2 weeks of CNI treatment. Similar efficacy of CNIs was observed even in 7 patients refractory to antitumor necrosis factor-alpha therapies. Endoscopic improvement was observed in 11 of 12 patients. Conclusions: CNIs may be promising treatment options for refractory intestinal BD.

  • Effectiveness and Durability of Ustekinumab Therapy With or Without Immunomodulators for Ulcerative Colitis Patients in Japan

    Aoki Y., Sujino T., Kawaguchi T., Sugimoto S., Shimada F., Yoshimatsu Y., Kiyohara H., Nanki K., Mikami Y., Takabayashi K., Hosoe N., Ogata H., Iwao Y., Kanai T.

    Crohn's and Colitis 360 (Crohn's and Colitis 360)  4 ( 2 )  2022年04月

     概要を見る

    Background and Aims: The effectiveness and durability of ustekinumab therapy with or without thiopurine immunomodulators (IMs) for ulcerative colitis (UC) in real-world Asian, Japanese patients have not yet been elucidated. Methods: To evaluate the additive effects of IMs on ustekinumab, a retrospective cohort study of UC patients receiving ustekinumab with or without thiopurine IMs, azathioprine or 6-mercaptopurine, was conducted from March 2020 to August 2021. The primary endpoint was clinical remission or response rate at week 8. The secondary endpoints were clinical remission or response rates at weeks 24 and 52, the durability of each treatment, and adverse events. Results: Of the 50 patients with UC treated with ustekinumab, 42 were enrolled. Sixteen patients were treated with a combination of ustekinumab and an IM. The clinical response rates of all patients at weeks 8, 24, and 52 were 53.7%, 63.3%, and 42.9%, respectively. There was no significant difference in the clinical responses or remission rates between the combination therapy and monotherapy groups at weeks 8, 24, and 52. (50.0% vs. 56.0%, P =. 757; 70.0% vs. 60.0%, P =. 702; and 42.9% vs. 42.9%, P = 1.00, respectively). A Kaplan-Meier analysis showed no difference in IM use on the durability of ustekinumab treatment (log-rank test; P =. 955). Conclusions: The response rate for Japanese UC patients is similar to previous reports based on American and European UC patients. There was no significant difference between the ustekinumab monotherapy group and the ustekinumab and IM combination group in the real world.

  • Organoid Medicine for Inflammatory Bowel Disease.

    Wakisaka Y, Sugimoto S, Sato T

    Stem cells (Dayton, Ohio) (Stem cells (Dayton, Ohio))  40 ( 2 ) 123 - 132 2022年03月

    ISSN  1066-5099

     概要を見る

    Inflammatory bowel disease (IBD) is a chronic relapsing-remitting inflammatory disease of the gastrointestinal tract with an unknown etiology, and its incidence is increasing worldwide. Recent advances in immunomodulatory therapeutic agents such as biologics and small-molecule inhibitors have improved the prognosis of patients with IBD. However, some patients are refractory and resistant to these immunomodulatory therapies, and new therapies are needed. Given the importance of the intestinal epithelium in IBD pathogenesis, the difficulty of culturing intestinal epithelial cells (IECs) for long periods remains an obstacle in IBD research. Over the past 15 years, intestinal stem cells have been identified, and the in vivo microenvironment, called the niche, required for their maintenance has been elucidated, making the permanent culture of IECs possible. Recapitulating the niche in vitro, the intestinal epithelium forms 3-dimensional structures called organoids that simulate the intestinal epithelium in vivo. The intestinal epithelium plays an important role in the intestinal barrier and immunomodulatory functions and serves as a physical structure that separates the intestinal lumen from the body. Recent studies have revealed that functional disruption of the intestinal epithelium is closely related to the pathogenesis of IBD, and IBD research using organoids has attracted attention. In this review, we discuss the application of adult tissue-derived organoids culture technology to elucidate the pathogenesis of IBD and to develop novel therapies, including regenerative treatments.

  • Texture and Color Enhancement Imaging combination with indigo carmine dye spraying highlighted the border of flat ulcerative colitis-associated neoplasia.

    Takabayashi K, Kato M, Sugimoto S, Yahagi N, Kanai T

    Gastrointestinal endoscopy (Gastrointestinal Endoscopy)  95 ( 6 ) 1273 - 1275 2022年02月

    ISSN  0016-5107

全件表示 >>

総説・解説等 【 表示 / 非表示

全件表示 >>

競争的研究費の研究課題 【 表示 / 非表示

  • 短腸症候群モデルを用いた新規移植療法の開発

    2021年07月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 挑戦的研究(萌芽), 補助金,  研究代表者

  • 小腸上皮オルガノイドにより創出した移植グラフトの機能解析

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 基盤研究(B), 補助金,  研究代表者

  • 腸管AhRワールドの解明

    2019年02月
    -
    2021年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 金井 隆典, 国際共同研究加速基金(国際共同研究強化(B)), 研究分担者

  • 腸管上皮-間質ニッチの包括的理解と自己補完的組織培養技術の確立

    2015年04月
    -
    2018年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 杉本 真也, 特別研究員奨励費, 補助金,  研究代表者

受賞 【 表示 / 非表示

  • 若手奨励賞

    2022年10月, 第30回日本消化器関連学会週間(JDDW 2022 FUKUOKA)

    受賞区分: 国内学会・会議・シンポジウム等の賞

  • 第5回同窓会賞(基礎研究分野 猿田享男賞)

    2022年07月, 慶應義塾大学医学部内科学教室

    受賞区分: 塾内表彰等

  • The 11th JSGE-UEG Rising Stars

    2022年04月, The Japanese Society of Gastroenterology - United European Gastroenterology

    受賞区分: 国際学会・会議・シンポジウム等の賞

  • 令和4年度 科学技術分野の文部科学大臣表彰 若手科学者賞

    2022年04月

    受賞区分: その他

  • Best Presentation Award

    2022年03月, Keio University Research Grants for Medicine and the Life Science

    受賞区分: 塾内表彰等

全件表示 >>

 

担当授業科目 【 表示 / 非表示

  • 内科学(消化器)講義

    2022年度